Placebo News and Research

RSS

Smokers with a history of major depressive disorder (MDD) taking varenicline have significantly higher likelihood of quitting smoking than placebo

Results of a Pfizer-commissioned study published this month in Annals of Internal Medicine reveal that smokers with a past or present diagnosis of major depressive disorder (MDD)* taking varenicline had a significantly higher likelihood of quitting smoking (after 12 weeks and at 52 weeks) than those who were given a placebo.

18 Sep 2013

Research: Steroids in spinal shots may not provide relief from lower back pain

New research from Johns Hopkins suggests that it may not be the steroids in spinal shots that provide relief from lower back pain, but the mere introduction of any of a number of fluids, such as anesthetics and saline, to the space around the spinal cord.

18 Sep 2013

Creabilis treats first atopic dermatitis patients in CT327 Phase 2b study

Creabilis, a late clinical stage European dermatology company with a focus on pruritus (itch), today announces it has treated the first patients in its Phase 2b study of its lead product, CT327, in patients with atopic dermatitis.

18 Sep 2013

Efficacy and safety data on linagliptin and investigational compound empagliflozin* in various diabetes subpopulations presented by Boehringer Ingelheim and Eli Lilly and Company

Boehringer Ingelheim and Eli Lilly and Company today announced they will feature five oral and 12 poster presentations for linagliptin and the investigational compound empagliflozin* at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD) which will take place in Barcelona, from 23 – 27 September. The presentations will add to the already existing body of data on safety and efficacy of these two compounds.

18 Sep 2013

FDA grants Breakthrough Therapy designation to Boehringer Ingelheim's volasertib

Boehringer Ingelheim Pharmaceuticals, Inc. today announced the FDA has granted Breakthrough Therapy designation to volasertib, an investigational inhibitor of polo-like kinase, being evaluated for the treatment of patients aged 65 or older with previously untreated acute myeloid leukemia, ineligible for intensive remission induction therapy.

17 Sep 2013

Dendreon Gets Green Light In Europe

...

17 Sep 2013

Dendreon Gets Greenlight In Europe

...

17 Sep 2013

Acacia Pharma initiates two pivotal Phase 3 studies of APD421 in prevention of PONV

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces the initiation of two pivotal Phase 3 studies of APD421 in the prevention of post-operative nausea & vomiting (PONV).

17 Sep 2013

Varenicline drug helps people with depression quit smoking, say researchers

About half of smokers seeking treatment for smoking cessation have a history of depression. Compared with smokers who are not depressed, those who suffer from a major depressive disorder have greater difficulty quitting.

17 Sep 2013

Arginine therapy may be safe treatment for patients with sickle cell disease

Arginine therapy may be a safe and inexpensive treatment for acute pain episodes in patients with sickle cell disease, according to results of a recent clinical study. The study was the first randomized placebo-controlled study to demonstrate benefits of arginine therapy in children with sickle cell disease hospitalized for severe pain.

17 Sep 2013

New behavioral therapy improves antidepressant treatment of OCD

NIMH grantees have demonstrated that a form of behavioral therapy can augment antidepressant treatment of obsessive compulsive disorder (OCD) better than an antipsychotic.

13 Sep 2013

Omeros announces positive data from OMS824 Phase 1 clinical trial

Omeros Corporation today announced positive data from the Company's Phase 1 clinical trial evaluating the pharmacokinetics of OMS824, the lead compound in Omeros' phosphodiesterase 10 program, further supporting that OMS824 can achieve superior target engagement with lesser side effects compared to other PDE10 inhibitors in development.

12 Sep 2013

Botox Cosmetic receives FDA approval for treatment of crow’s feet lines

The U.S. Food and Drug Administration today approved a new use for Botox Cosmetic (onabotulinumtoxinA) for the temporary improvement in the appearance of moderate to severe lateral canthal lines, known as crow’s feet, in adults. Botox Cosmetic is the only FDA approved drug treatment option for lateral canthal lines.

12 Sep 2013

Circassia: House dust mite allergy treatment meets primary endpoint in phase II clinical study

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced successful results from a phase II clinical study of its house dust mite allergy treatment (House Dust Mite-Synthetic Peptide Immuno-Regulatory Epitope [HDM-SPIRE] based on Circassia’s ToleroMune technology).

12 Sep 2013

Hydroxyurea treatment prevents complications, lowers medical care costs in children sickle cell disease

The benefits of hydroxyurea treatment in people with sickle cell disease are well known -- fewer painful episodes, fewer blood transfusions and fewer hospitalizations. Now new research from the Johns Hopkins Children's Center and other institutions reveals that by preventing such complications, the drug can also considerably lower the overall cost of medical care in children with this condition.

12 Sep 2013

FDA grants Breakthrough Therapy designation to Syndax's entinostat for ER+ breast cancer

Syndax Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration has designated entinostat as a Breakthrough Therapy for the treatment of locally recurrent or metastatic estrogen receptor-positive (ER+) breast cancer when added to exemestane in postmenopausal women whose disease has progressed following non-steroidal aromatase inhibitor therapy.

12 Sep 2013

MicroBiome Therapeutics' NM504 eliminates diarrhea caused by metformin in type 2 diabetes patient

MicroBiome Therapeutics LLC, a biotechnology company developing pharmaceutical and medical food products that shift the human microbiome in specific ways for improved health, today reported publication of a case report suggesting a potentially important new application for its lead product, NM504. NM504 is in clinical development to promote healthy blood glucose levels and metabolic fitness in prediabetic and diabetic populations.

11 Sep 2013

Improved lung function in patients with moderate asthma severity observed with investigational Tiotropium

Boehringer Ingelheim will present a pooled analysis of new data from the Phase 3 UniTinA-asthma® program at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona. The data from the individual MezzoTinA-asthma® Phase 3 studies (NCT01340209 and NCT00565266), from which the pooled data are derived, show the addition of tiotropium delivered via the Respimat® inhaler to medium-dose maintenance inhaled corticosteroid (ICS) therapy (defined as 400-800 µg budesonide/day or equivalent) improved lung function and provided sustained bronchodilation over 24 hours in patients with moderate asthma and airflow limitation. Tiotropium is being investigated to determine the medicine’s efficacy in treating asthma patients and is not currently approved for this indication.

11 Sep 2013

Combination drug does not improve survival in patients with severe alcoholic hepatitis

Four weeks of treatment with a combination of the drug pentoxifylline and the corticosteroid prednisolone did not improve 6-month survival compared with prednisolone alone in 270 patients with severe alcoholic hepatitis, according to a study in the September 11 issue of JAMA.

11 Sep 2013

Patients with COPD show improvements in lung function with olodaterol

Data from the olodaterol Phase 3 clinical program, presented for the first time at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona, showed the addition of olodaterol 5 and 10 µg delivered once daily via the Respimat® inhaler provided improvements in lung function in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

10 Sep 2013

Placebo News and Research

Smokers with a history of major depressive disorder (MDD) taking varenicline have significantly higher likelihood of quitting smoking than placebo

Research: Steroids in spinal shots may not provide relief from lower back pain

Creabilis treats first atopic dermatitis patients in CT327 Phase 2b study

Efficacy and safety data on linagliptin and investigational compound empagliflozin* in various diabetes subpopulations presented by Boehringer Ingelheim and Eli Lilly and Company

FDA grants Breakthrough Therapy designation to Boehringer Ingelheim's volasertib

Dendreon Gets Green Light In Europe

Dendreon Gets Greenlight In Europe

Acacia Pharma initiates two pivotal Phase 3 studies of APD421 in prevention of PONV

Varenicline drug helps people with depression quit smoking, say researchers

Arginine therapy may be safe treatment for patients with sickle cell disease

New behavioral therapy improves antidepressant treatment of OCD

Omeros announces positive data from OMS824 Phase 1 clinical trial

Botox Cosmetic receives FDA approval for treatment of crow’s feet lines

Circassia: House dust mite allergy treatment meets primary endpoint in phase II clinical study

Hydroxyurea treatment prevents complications, lowers medical care costs in children sickle cell disease

FDA grants Breakthrough Therapy designation to Syndax's entinostat for ER+ breast cancer

MicroBiome Therapeutics' NM504 eliminates diarrhea caused by metformin in type 2 diabetes patient

Improved lung function in patients with moderate asthma severity observed with investigational Tiotropium

Combination drug does not improve survival in patients with severe alcoholic hepatitis

Patients with COPD show improvements in lung function with olodaterol

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News